Beneficient 8-K filings

Beneficient announced its first quarter fiscal 2027 results, featuring a new collateral management services engagement and over $16 million in primary capital commitments, alongside reduced operating expenses.

Beneficient has issued two $2.0 million convertible promissory notes to YA II PN, Ltd. as part of an amended standby equity purchase agreement, raising a total of $4.0 million.

Beneficient announced the closing of a $7.44 million primary capital commitment to Quartus AI Fund II LP, furthering its strategy in AI-focused investments.

Beneficient has amended its Standby Equity Purchase Agreement with Yorkville, reducing the potential equity sale to $100 million and issuing a $2 million convertible promissory note.

Beneficient reported fiscal year 2026 results, highlighting the resolution of GWG Holdings litigation, over $50 million in asset sale proceeds, and a focus on expanding its primary capital solutions and collateral management services.

Beneficient has launched its collateral management services with a new engagement for a Texas state-chartered bank.

Beneficient has amended its previous 8-K filing to confirm the appointment of Mack Hicks to the Executive and Nominating Committees.

Beneficient announced the closing of an $8.75 million primary capital commitment in Quartus AI Fund LP, receiving Series B-10 Preferred Stock convertible into Class A Common Stock.

Beneficient's stockholders approved an amendment to its 2023 Long Term Incentive Plan, increasing share reserves, and re-elected three Class A directors at the annual meeting on March 27, 2026.

Beneficient amended its credit agreement, settling remaining debt with a mix of stock and deferred cash payments, and appointed Mack Hicks, an affiliate's CEO, to its Board of Directors.

Beneficient announced that the U.S. District Court for the Northern District of Texas has approved the previously disclosed settlement resolving all GWG Holdings, Inc. related claims against the company.

Beneficient announced the early repayment of approximately $27.5 million in loans, enhancing its financial flexibility and balance sheet.

Beneficient announced the closing of a $3 million primary capital transaction, issuing Series B-9 Resettable Convertible Preferred Stock in exchange for a limited partner interest in an investment fund.

Beneficient announced it has regained full compliance with Nasdaq's minimum bid price and warrant listing requirements, ensuring its continued listing on The Nasdaq Capital Market.

Beneficient announced the appointment of Peter T. Cangany Jr., a seasoned financial services expert, as the new Chairman of its Board of Directors, effective December 15, 2025.

Beneficient will implement a 1-for-8 reverse stock split effective December 15, 2025, to regain compliance with Nasdaq's minimum bid price requirement.

Beneficient announced the passing of Thomas O. Hicks, Chairman of its Board of Directors, a pioneer in private equity and a dedicated leader.

Beneficient's stockholders approved a reverse stock split and a potential meeting adjournment at a Special Meeting held on December 1, 2025.

Beneficient announced its second quarter fiscal 2026 financial results, highlighting improved cost management, capital structure enhancements, and regaining compliance with Nasdaq listing requirements.

Beneficient announced the indictment of its former Chairman and CEO, Brad Heppner, by the U.S. Attorney for the Southern District of New York, stating the company had previously parted ways with him due to fraud allegations.

Beneficient announced it has regained compliance with Nasdaq's periodic filing and market value requirements but remains non-compliant with the $1.00 bid price rule, planning a reverse stock split.

Beneficient's Chairman and Interim CEO converted $52.6 million of preferred units into common stock, aiming to simplify the capital structure and address Nasdaq listing requirements.

Beneficient announced its first quarter fiscal 2026 financial results, emphasizing improved cost management, new primary capital transactions, and a strengthened financial foundation.

Beneficient received a Nasdaq delisting notice for negative stockholders' equity, compounding existing non-compliance issues with periodic filings and bid price requirements.

Beneficient announced a transformative fiscal year 2025, marked by significantly reduced operating costs, resolution of major legal issues, and strategic positioning for future growth.

Beneficient has been granted an extension by Nasdaq to regain compliance with periodic reporting and minimum bid price requirements, avoiding immediate delisting.

Beneficient received an additional Nasdaq delisting notice for failing to file its Q2 2025 report, compounding existing bid price and annual report filing deficiencies.

Beneficient received notice of default on $94.4 million in credit agreements, triggering cross-defaults and prompting an investigation into alleged fraudulent conduct by its former CEO.

Beneficient announced the appointment of James G. Silk as interim Chief Executive Officer and Thomas O. Hicks as Chairman of the Board, following the departure of former CEO and Chairman Brad Heppner.

Beneficient received a delisting notice from Nasdaq due to its Class A common stock trading below the $1.00 minimum bid price and its failure to timely file its Annual Report on Form 10-K.